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Just another chalazion?
Case

A 60‑year‑old Caucasian male noted a red lesion on the right
lower eyelid which was growing over 3 months. He revealed
previously treated cancers of the colon, ureter, and skin, all under
control without recurrence. He also noted previous eyelid surgery
2 years ago revealing a well‑differentiated sebaceous carcinoma.
Family history disclosed multiple members with skin and colon
carcinomas. On examination of the patient, visual acuity was 20/20
OD and 20/30 OS. There was an elevated, lightly colored cutaneous
lesion on the right lower eyelid margin, temporal to the site of the
previous biopsy and measuring 6 × 4 × 3 mm.

What is your next step?

A. Shave biopsy of the lesion and follow up in 3 months.
B. Wedge resection with immunohistochemical testing for
Muir‑Torre syndrome (MTS).
C. Close monitoring with daily applications of hot compresses
and topical corticosteroid ointment.
D. Test for Gorlin–Goltz syndrome and proceed with photodynamic
therapy.

Findings

A pentagonal eyelid resection of the mass [Fig. 1a and b] was performed.
Histopathology revealed a low‑grade sebaceous neoplasm most
consistent with sebaceous adenoma. Immunohistochemical
testing for DNA mismatch repair proteins in the excised tissue
demonstrated normal staining for MLH1 [Fig. 1c] and abnormal
absence (lack of staining, mutation) for MSH2 [Fig. 1d]. These
findings were suggestive of underlying MTS.
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Figure 1: External photograph showing nodular lesion on the right
lower lid margin (a) and invading the tarsus (b). Immunohistochemical
staining for DNA mismatch repair proteins revealed normal staining
for MLH1 (c) and lack of staining for MSH2 (d), suggestive of MuirTorre syndrome
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MTS is a rare variant of Lynch syndrome found in <1% of
the population. This syndrome is clinically suspected by the
occurrence of both a visceral cancer, usually involving the colon or
genitourinary system, along with cutaneous sebaceous neoplasms.
This constellation of neoplasms is typically multiple, occur at an early
age, and are generally histopathologically low grade.[1] Colorectal
carcinoma is the most common primary malignancy, found in
approximately 51% of MTS patients and generally localized proximal
to the splenic flexure.[2] Other common internal malignancies include
cancer of the endometrium, ovary, and uroepithelium which make
up 24% of cases. Mismatch repair gene mutations in MLH1 and
MSH2 spawn the development of various neoplasms.[3]
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